Academic Journals Database
Disseminating quality controlled scientific knowledge

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

Author(s): Shemesh G | Moisseiev E, Lazar M | Kurtz S

Journal: Clinical Ophthalmology
ISSN 1177-5467

Volume: 2012;
Issue: default;
Start page: 283;
Date: 2012;
Original page

Gabi Shemesh*, Elad Moisseiev*, Moshe Lazar1, Shimon Kurtz Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*The first two authors contributed equallyPurpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day.Methods: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded.Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.Keywords: Cosopt, timolol, dorzolamide, glaucoma, intraocular pressure, dosage

Tango Jona
Tangokurs Rapperswil-Jona

     Affiliate Program